This new regulatory approval for GelX is the first for a medical product to be used for both the treatment and prevention of oral mucositis in cancer patients.
Contributed Author:
BMG Pharma S.r.l.
Topics:
More From BioPortfolio on "GelX Approved In Europe For Prevention Of Oral Mucositis In Cancer Patients"